Published in final edited form as:

Clin Exp Allergy. 2012 May ; 42(5): 760–768. doi:10.1111/j.1365-2222.2011.03860.x.

Nitric oxide and related enzymes in asthma: Relation to severity, enzyme function and inflammation

Mayumi Yamamoto, M.D., Ph.D.¹⁾, Yoshihiro Tochino, M.D., Ph.D.¹⁾, Kazuyuki Chibana, M.D., Ph.D.¹⁾, John B Trudeau, B.A.¹⁾, Fernando Holguin, M.D.¹⁾, and Sally E Wenzel, M.D.¹⁾

¹⁾University of Pittsburgh Asthma Institute, University of Pittsburgh Medical Center, Pittsburgh, PA

Abstract

Background—Exhaled nitric oxide (FeNO) associates with asthma and eosinophilic inflammation. However, relationships between nitric oxide synthases, arginase, FeNO, asthma severity and inflammation remain poorly understood.

Objectives—To determine the relationships of iNOS expression/activation and arginase 2 expression with asthma severity, FeNO, nitrotyrosine (NT) and eosinophilic inflammation.

Methods—Bronchial brushings and sputum were obtained from 25 Normal Controls, 8 Mild/no inhaled corticosteroids (ICS), 16 Mild-Moderate/with ICS and 35 Severe Asthmatics. FeNO was measured the same day by ATS/ERS standards. iNOS, Arginase2 mRNA/protein and NT protein were measured in lysates from bronchial brushings by quantitative real time PCR and Western Blot. Induced sputum differentials were obtained.

Results—Severe asthma was associated with the highest levels of iNOS protein and mRNA, although the index of iNOS mRNA to arginase2 mRNA most strongly differentiated severe from milder asthma. When evaluating NO-related enzyme functionality, iNOS mRNA/protein expression both strongly predicted FeNO ($r=0.61$, $p<0.0001$ for both). Only iNOS protein predicted NT levels ($r=0.48$, $p=0.003$) with the strongest relationship in severe asthma ($r=0.61$, $p=0.009$). iNOS protein, FeNO and NT all correlated with sputum eosinophils, but the relationships were again strongest in severe asthma. Controlling for arginase 2 mRNA/protein did not impact any functional outcome.

Conclusions and Clinical Relevance—These data suggest that while iNOS expression from epithelial brushings is highest in severe asthma, factors controlling arginase2 mRNA expression significantly improve differentiation of severity. In contrast, functionality of the NO pathway as measured by FeNO, NT and eosinophilic inflammation, is strongly associated with iNOS expression alone, particularly in severe asthma.

Keywords

exhaled nitric oxide; airway epithelial cells; iNOS; arginase 2; nitrotyrosine

Introduction

Asthma is a chronic inflammatory disease associated with increased airway eosinophils. Exhaled nitric oxide (FeNO) associates with asthma and modestly correlates with

Sally E Wenzel, M.D., University of Pittsburgh Asthma Institute, University of Pittsburgh Medical Center, 3459 Fifth Ave. Pittsburgh, PA 15213, wenzelse@upmc.edu, Phone: +1-412-692-2661, Fax: +1-412-692-2260.

Conflict of Interest. Drs. Yamamoto, Tochino, Chibana Holguin, Wenzel and Mr. Trudeau have no conflicts of interest of relevance to this manuscript.

eosinophilic inflammation, but these relationships are complex. FeNO has not been reported to associate directly with asthma severity [1], but identifies a group with eosinophilic inflammation (on and off inhaled corticosteroids (ICS)) [2–5]. While FeNO generally decreases with ICS therapy, when elevated in severe asthma despite corticosteroid (CS) therapy, it identifies a group with more airway obstruction, eosinophilia and urgent health care utilization [1]. In each case, the relationship of FeNO to levels of its regulatory enzymes, inducible nitric oxide synthase and arginase, is not known.

FeNO levels directly depend on nitric oxide synthases (NOS) to generate nitric oxide (NO). Inducible NOS (iNOS) is believed to be the primary enzyme responsible for generation of FeNO and human airway epithelial cells express iNOS mRNA and protein [6–7]. The Th2 cytokine interleukin (IL)-13 robustly induces the expression of an active dimeric iNOS enzyme in primary human airway epithelial cells maintained in air-liquid interface (ALI) culture, consistent with its expression in relation to "allergic/Th2" inflammation [8]. However, the relationship of iNOS expression to FeNO and asthma severity has not yet been addressed.

Arginases have also been suggested to influence FeNO levels by limiting the availability of arginine for NO generation. An increase in arginase activity in more severe asthma has been suggested to limit substrate for iNOS, which uncouples NOS leading to diminished NO levels while increasing peroxynitrite and downstream protein nitrosylation [9–10]. However, the relationship between iNOS, arginase, FeNO and nitrosylated proteins in the airways of asthmatics of varying severity has not been addressed. The specific arginase involved is also not known, although arginase 2 was recently reported to be present in higher amounts than arginase I in primary cultured human airway epithelial cells [8, 11–13].

We therefore hypothesized that epithelial expression of iNOS protein/mRNA would predict asthma severity and FeNO, while adjusting for arginase expression would improve these relationships. The function of these enzymes in relation to FeNO, NT levels and sputum eosinophils was also addressed. To accomplish this, iNOS and arginase 2 mRNA/protein expression were measured in fresh airway epithelial cells from carefully phenotyped asthmatic and control subjects and compared to FeNO, sputum eosinophils and in a subset, nitrated proteins.

Methods

Subjects

Asthmatic subjects all met American Thoracic Society criteria and were recruited as part of the Severe Asthma Research Program. All subjects met criteria for asthma including either a 12% (and >200 ml) improvement in FEV₁ post bronchodilator and/or a positive methacholine (PC₂₀<16 mg/ml). Mild asthma subjects (Mild) had an FEV₁ of ≥80% predicted and used inhaled β-agonists alone. Mild-Moderate (Mild/Mod+ICS) asthmatics had an FEV₁ of >60% predicted on low/moderate inhaled CS (ICS). Severe asthmatic subjects were referred to National Jewish Medical and Research Center or the University of Pittsburgh for refractory asthma and met the ATS workshop definition for severe asthma, including the continuous use of high dose continuous ICS and/or frequent use of oral CS with continuing symptoms, frequent symptoms and/or chronic airflow limitation [14]. Normal control (NC) subjects all had no history of respiratory disease or recent respiratory infection, normal lung function and no evidence of bronchial hyperresponsiveness. All normal control subjects underwent methacholine challenge and only normal subjects with a PC₂₀ of >25 mg/ml were allowed to continue to bronchoscopy. No subject smoked within the last year or had a history of smoking >5 pack years. The study was approved by the

National Jewish and the University of Pittsburgh Institutional Review Boards and all subjects gave informed consent.

Exhaled NO

FeNO was measured using a NIOX (Aerocrine, New York, NY) (NJC) or Logan analyzer (Logan, London, UK) following ATS guidelines at a flow rate of 50 ml/s. FeNO was measured before bronchodilator administration on the same day as the collection of bronchial epithelial cell mix.

Bronchoscopy with endbronchial airway brushings

Bronchoscopy with endobronchial epithelial brushing was performed as previously described [8] [15]. The bronchial brushings, >95% epithelial cells, but intermixed with inflammatory cells, as well, were placed into Trizol for mRNA and Western Lysis Buffer for protein evaluation. The mixed cell population will be referred to as “mixed epithelial cells”, or “bronchial brushings” throughout the remainder of the text.

Quantitative Real-Time PCR

The mixed epithelial expression of iNOS and arginase 1, 2 mRNA was determined by reverse transcription (RT), followed by real-time quantitative PCR as described previously. The primers and probes, labeled with 5'-reporter dye 6-carboxy fluorescein (FAM) and 3'-quencher dye 6-carboxy N, N, N',N'-tetramethyl-rhodamine (TAMRA), were all purchased from Applied Biosystems (Assays on Demand, Foster City, CA). (Catalog #: iNOS, Hs00167248_m1, arginase 2, Hs00265750_m1, arginase 1, Hs00163660_m1). VIC-labeled ready-for-use human GAPDH primers and probe were obtained from Applied Biosystems (Genbank accession no: NM-002046, Catalog #: 4310884E). Real-time PCR was performed on the ABI Prism 7700 or 7900 sequence detection system (Applied Biosystems, Foster City, CA). mRNAs of interest were indexed to GAPDH using the formula $1/(2^{\Delta CT}) \times 1000$.

Western Blots for iNOS arginase and nitrotyrosine

Samples were resolved on 10% SDS-PAGE, transferred and immuno-probed with rabbit polyclonal antibody for iNOS (1:500, BD Transduction Laboratories), arginase 1 and 2 (1:500, Santa Cruz Biotechnology) and nitrotyrosine (NT) (1:500, Calbiochem). Horseradish peroxidase (HRP) conjugated secondary antibody (F(ab')₂) (1:4000) was followed by ECL Plus Western blot detection reagent (Amersham, Buckinghamshare, UK) and chemiluminescence detected by Luminocent image analyzer, LAS-3000 (Fuji Film, Tokyo, Japan). Blots were stripped and re-probed for β -actin (1:5000, Sigma, St Louis, MO, USA). Densitometry was performed using the Multi Gage software (Fuji Film) and the protein of interest was indexed to β -actin.

Clinical Characteristics

Baseline spirometry testing was performed following a 4 to 6 hour withhold of short-acting bronchodilators and a 24-hour withhold on long-acting bronchodilators.

Sputum Eosinophil Measurements

Sputum was induced and processed per a variation of the Fahy method, typically 2–4 weeks prior to bronchoscopy [16]. Differentials were performed on 300 total cells counted by two blinded readers and eosinophils reported as percentage of total cells.

Statistics

As the majority of data were not normally distributed, data were analyzed using nonparametric tests. The Kruskal Wallis version of the Wilcoxon test was used to compare overall differences among the 4 groups (the overall p-value). When the overall p-value was <0.05 , intergroup comparisons were done using the Wilcoxon test with the conservative Bonferroni correction for multiple comparisons ($p<0.01$ considered significant). Spearman's correlation analysis was performed to evaluate relationships between iNOS, arginase 2 or iNOS/arginase 2 and FeNO, FEV1 %predicted or sputum eosinophils (%). For all comparisons, p-values <0.05 were considered significant.

Results

Subjects

Twenty-five NC, 8 Mild/no ICS, 16 Mild/Mod+ICS and 35 Severe asthma subjects underwent bronchoscopic airway brushing (Table 1). Severe asthma subjects were older than NC or Mild/Mod+ICS subjects ($p=0.01$). There were no differences in gender/race by group, but airway obstruction and sputum eosinophilia were greatest in the severe asthmatic group. Asthmatics were more likely to be atopic. Not all subject's cells were available for every experiment due to the limited numbers of mixed epithelial cells obtained at the time of brushing.

iNOS mRNA and Protein in Relation to Disease Severity

Freshly collected bronchial brushings were evaluated for iNOS mRNA and protein levels. iNOS mRNA and protein differed among the 4 groups (overall $p=0.0003$ for both) (Figures 1a and 1b). iNOS mRNA and protein were higher in Severe asthma than in NC ($p<0.0001$ for both). After Bonferroni correction, there were no differences in iNOS mRNA or protein among asthmatic groups. However, iNOS mRNA in Severe asthma tended to be higher than in Mild and Mild/Mod+ICS ($p=0.02$ for both), while iNOS protein only tended to be higher than in Mild/Mod+ICS ($p=0.02$). iNOS protein was significantly higher in asthmatics on oral CSs (OCS) (3.0 median, 25th–75th% 0.9–10.3) as compared to those not on oral CSs (1.0 (0.2–2.8) ($p=0.03$)), while iNOS mRNA was not ($p=0.1$). iNOS mRNA and protein correlated with each other in all subjects ($r=0.56$, $p<0.0001$) and in asthmatics alone ($r=0.53$, $p=0.0005$).

Arginase2 mRNA and Protein Expression in Relation to Disease Severity

Arginase 2 expression was targeted as bronchial brushing expression of arginase 1 mRNA and protein was weak and arginase 2 was more highly expressed in human epithelial cells *in vitro* (Figure 2) [8]. Arginase 2 mRNA did not differ between asthma and controls or between categories of asthma severity, however, there was a tendency for Arginase 2 mRNA to decrease with increasing asthma severity (overall $p=0.17$). Arginase 2 protein did not differ among groups ($p=0.61$), and there was no difference between those on and off oral CSs. Both arginase 2 mRNA and protein positively correlated with iNOS (iNOS to arginase 2 mRNA: $r=0.26$, $p=0.03$; iNOS to arginase 2 protein: $r=0.37$, $p=0.002$). However, arginase 2 mRNA and protein did not correlate with each other ($r=0.19$, $p=0.17$).

Controlling iNOS for Arginase 2 Expression in Relation to Asthma Severity

iNOS mRNA and protein were indexed for the level of arginase 2 mRNA and protein expression to determine whether this improved the relationship to asthma severity. Indexing iNOS to arginase 2 mRNA marginally improved the overall relationship ($p<0.0001$, Figure 3a), but now strongly differentiated Severe from NC ($p<0.001$), Mild ($p=0.006$) and Mild/Mod+ICS asthma ($p=0.003$). Indexing iNOS protein to arginase 2 protein also slightly

improved the overall p-value ($p=0.0002$) (Figure 3b), but in contrast to the mRNA index, only differentiated both Severe ($p=0.0001$) and Mild asthmatics ($p=0.004$) from NC, without impacting differences between asthmatic groups. iNOS/arginase2 mRNA was also significantly higher in those asthmatics on OCS [7.9 (3.0–16.0)] compared to those not on OCS [1.2 (0.9–8.1)] ($p=0.04$), while the iNOS/arginase 2 protein index did not differ by OCS use ($p=0.1$).

iNOS Enzyme Products in Relation to Asthma Severity

As expected, FeNO was higher in asthmatic subjects (overall $p=0.01$) (Figure 4a). While severe asthmatics had higher levels than NCs ($p=0.001$), FeNO did not differ between asthmatic groups, nor was there an effect of OCS ($p=0.4$). Similarly, although total nitrated proteins (overall $p=0.06$) and the strong lower molecular weight 25kD band (overall $p=0.04$) did not differ among the asthma groups, only severe asthmatics differed from NC ($p=0.006$ and $p=0.005$, respectively for each band). There was no relationship to asthma severity or OCS use (Figure 4b).

iNOS and Arginase 2 Enzyme Expression in Relation to FeNO and NT (Table 2 and 3)

FeNO strongly correlated with both iNOS mRNA and protein in the overall population ($r=0.61$, $p<0.0001$ for both) and in both not severe and severe asthmatic subjects without difference by group. Arginase 2 mRNA or protein did not correlate with FeNO, nor did controlling iNOS mRNA or protein for arginase 2 expression improve correlations with FeNO over those of iNOS expression alone (Table 2). NT proteins levels (both total and 25kD) correlated with iNOS mRNA/protein in all subjects (Table 3), while the 25kD The NT band also correlated with FeNO. The relationships of iNOS mRNA with NT were absent in asthmatic alone, while the relationship of iNOS protein with NT was strongest in severe asthma and absent in not-severe asthma. None of these relationships improved when controlling iNOS for Arginase 2 mRNA/protein.

iNOS and Arginase Expression in Relation to Eosinophilic inflammation (Table 4)

Sputum eosinophil percentages marginally correlated with iNOS mRNA and protein ($r=0.33$, $p=0.009$, $r=0.30$, $p=0.03$ respectively) and NT ($r=0.36$, $p=0.048$), but were more strongly correlated with FeNO ($r=0.43$ $p=0.0003$). Stratifying by severity again showed these relationships to be significant only in severe asthma and absent in asthmatics without severe disease. Controlling for arginase2 did not improve any relationships.

Discussion

In this subpopulation of SARP participants, asthma severity was significantly associated with iNOS mRNA and protein, and to some degree with FeNO. However, while arginase 2 mRNA marginally and inversely correlated with severity, controlling iNOS mRNA for arginase 2 levels substantially improved the differentiation of severe from milder asthma. In contrast, the functionality of the pathway as measured by FeNO and NT levels was strongly related to iNOS protein in particular, with no impact when controlling for level of arginase 2 expression. Finally, sputum eosinophils were predicted by iNOS protein, FeNO and NT in severe asthma, but not in milder asthma, relationships also not improved by controlling for arginase. These findings suggest that although iNOS clearly associates with asthma and to some degree severe asthma, controlling iNOS mRNA for levels of arginase 2 expression best predicts asthma severity. In contrast, only levels and activity of the iNOS enzyme itself contribute to the functional read-outs of FeNO, NT and sputum eosinophils. Together, these data confirm an important but complex role for an active epithelial iNOS in asthma and severe asthma.

Both iNOS mRNA and protein expression were highest in severe asthma. Although iNOS expression in human airway epithelial cells (HAEC) has been described by immunohistochemistry and *in situ* hybridization, these methods are not suitable for quantification and thus were not utilized here [17–18]. Instead, we focused on standardized and quantifiable Western Blots and qRT-PCR, methods by which mRNA and protein levels correlated significantly. While evaluating enzyme function might also have been helpful, these assays are limited on fresh cells due to low numbers of cells available and in cultured cells, because of dedifferentiation which leads to indistinguishable iNOS or arginase levels in asthmatic vs normal cells [8].

Although significant increases in iNOS with increasing severity of asthma were not observed, sustained expression despite high dose CS therapy was present. The mechanisms sustaining this expression in the face of high dose inhaled and even OCS in the severe asthmatics studied here are not clear. Although FeNO is typically decreased by CS therapy, the impact of CS on iNOS is less clear [19–23]. In our study, iNOS mRNA, protein and to a lesser degree, FeNO remained high and incompletely suppressed by CS therapy even in milder asthma. Although persistent expression of FeNO (and iNOS) by CS in mild-moderate asthma may reflect poor CS compliance/adherence, the persistently high levels in severe asthma treated with high dose inhaled and OCS support more complex regulatory mechanisms. While Th2 cytokines are likely playing a role in the high iNOS expression/activity, the levels of Th2 cytokines in severe asthma, are generally low due to ongoing CS suppression [8, 24–26]. Interferon gamma (IFN γ), which reported to be increased in severe asthma, can also induce iNOS expression in submerged epithelial cells, an interaction enhanced by the Th2 cytokine IL-4 [27]. This interaction could also render the iNOS expression less CS responsive, an effect observed with other combined cytokine stimulations [28–29].

Arginase 2 was the prominent epithelial arginase with the mRNA showing a marginal decreasing trend with increasing severity of asthma, while protein did not differ between groups [8, 30–31]. Very little is known regarding arginase 2 regulation in human cells, although unlike iNOS, it is not impacted by IL-13 [8]. In non-human epithelial cells, arginase 2 was impacted by bacterial infection and CSs [32–37]. The factors which could suppress arginase 2 in asthma (including CSs) require further study but may explain why the ratio of iNOS to arginase 2 mRNA better defines severe asthma than either mRNA alone. Thus, when iNOS mRNA (but not protein) was controlled for arginase 2 expression, the association with asthma severity improved substantially. The reasons that controlling iNOS mRNA for arginase mRNA improves the relationship to asthma severity are not clear. However, the lack of improvement when controlling iNOS protein for arginase 2 protein, or when addressing the relationship to functional outcomes, suggests that the improved relationship is not likely due to the levels and activity of arginase 2. More likely it reflects an inflammatory (and CS influenced) cytokine milieu which increases iNOS while suppressing arginase 2 mRNA expression.

In addition to the relation to severity, we also addressed the relation of enzyme expression to enzyme function, as measured by FeNO, NT and eosinophilic inflammation. Both iNOS mRNA and protein strongly predicted FeNO without difference by subject group or influence by arginase 2 expression. iNOS protein (but not mRNA), as well as FeNO, also predicted NT, with the strongest relationships in severe asthma. This strong positive relationship of FeNO with NT in severe asthma and the lack of evidence for increased arginase 2 expression do not support the hypothesis that “relatively” low FeNO levels in more severe asthma are due to increased expression/activity of arginases, as has been reported in cystic fibrosis where FeNO and NT levels were inversely related [38]. That theory suggests that low arginine levels (the substrate for both iNOS and arginase) in severe

asthma would drive arginine to peroxynitrite at the expense of FeNO [30, 39]. In contrast, the strong correlations of FeNO and NT with iNOS protein suggest that the conversion to NT is due to higher iNOS expression and FeNO generation, in the setting of the increased oxidative stress reported in severe asthma [40–42]. This increased oxidative stress would favor production of the reactive mediator peroxynitrite from an overabundance of NO. This would allow protein nitration to occur, contributing to the strong relationship of NO with NT [43–44]. The absence of these relationships between iNOS, FeNO and NT in mild asthma supports this hypothesis.

iNOS protein, FeNO and NT also predicted sputum eosinophilia. These relationships again were only present in severe asthma and not in milder asthma. The reasons for the better relationship of iNOS protein (and FeNO) to eosinophils in severe asthma may merely identify a strong parallel Th2 presence. However, the striking relationship of NT to eosinophils in severe asthma also supports a relationship of eosinophilic inflammation to the oxidative stress referenced above [45]. The exact nature of the nitrated proteins in our mixed epithelial samples remains to be determined.

The limitations from this study include its cross sectional study design, without ability to look at effects of CSs before and after use, as well as the lack of any data on subject adherence to CSs. The time between the induced sputum and the bronchoscopy varied, and a more even distribution of subjects across severity categories would have been preferred. Finally, the identification of the nitrated proteins remains to be completed

In conclusion, iNOS mRNA, protein from bronchial brushings and FeNO modestly differentiated asthma severity, while controlling for arginase 2 mRNA significantly improved the prediction of severe asthma. In contrast, controlling for arginase 2 expression did not influence the functionality of the NO pathway. The strong functional relationships between iNOS protein, FeNO, NT and eosinophils in severe asthma suggest a complex CS refractory immunoinflammatory process which differs from that seen in milder asthma. Further studies are required to understand these processes.

Acknowledgments

Funding Source: NIH AI-067780 and HL-069174 and CTSI UL1-RR024153

References

1. Dweik RA, Sorkness RL, Wenzel S, Hammel J, Curran-Everett D, Comhair SA, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. *Am J Respir Crit Care Med*. 2010; 181(10):1033–41. [PubMed: 20133930]
2. Silkoff PE, Lent AM, Busacker AA, Katial RK, Balzar S, Strand M, et al. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. *J Allergy Clin Immunol*. 2005; 116(6):1249–55. [PubMed: 16337453]
3. Berry MA, Shaw DE, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. *Clin Exp Allergy*. 2005; 35(9):1175–9. [PubMed: 16164444]
4. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. *Thorax*. 1998; 53(2):91–5. [PubMed: 9624291]
5. Lex C, Ferreira F, Zacharasiewicz A, Nicholson AG, Haslam PL, Wilson NM, Hansel TT, Payne DN, Bush A. Airway eosinophilia in children with severe asthma: predictive values of noninvasive tests. *Am J Respir Crit Care Med*. 2006; 174(12):1286–91. [PubMed: 16973985]

6. Gabbay E, Haydn Walters E, Orsida B, Whitford H, Ward C, Kotsimbos TC, et al. In stable lung transplant recipients, exhaled nitric oxide levels positively correlate with airway neutrophilia and bronchial epithelial iNOS. *Am J Respir Crit Care Med*. 1999; 160(6):2093–9. [PubMed: 10588634]
7. Guo FH, Comhair SA, Zheng S, Dweik RA, Eissa NT, Thomassen MJ, et al. Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis. *J Immunol*. 2000; 164(11):5970–80. [PubMed: 10820280]
8. Chibana K, Trudeau JB, Mustovich AT, Hu H, Zhao J, Balzar S, et al. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. *Clin Exp Allergy*. 2008; 38(6): 936–46. [PubMed: 18384429]
9. Meurs H, Maarsingh H, Zaagsma J. Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness. *Trends Pharmacol Sci*. 2003; 24(9):450–5. [PubMed: 12967769]
10. Maarsingh H, Zaagsma J, Meurs H. Arginine homeostasis in allergic asthma. *Eur J Pharmacol*. 2008; 585(2–3):375–84. [PubMed: 18410920]
11. Iyer R, Jenkinson CP, Vockley JG, Kern RM, Grody WW, Cederbaum S. The human arginases and arginase deficiency. *J Inher Metab Dis*. 1998; 21 (Suppl 1):86–100. [PubMed: 9686347]
12. Zimmermann N, Rothenberg ME. The arginine-arginase balance in asthma and lung inflammation. *Eur J Pharmacol*. 2006; 533(1–3):253–62. [PubMed: 16458291]
13. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. *Biochem J*. 1998; 336 (Pt 1): 1–17. [PubMed: 9806879]
14. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. *Am J Respir Crit Care Med*. 2000; 162(6):2341–51. [PubMed: 11112161]
15. Trudeau J, Hu H, Chibana K, Chu HW, Westcott JY, Wenzel SE. Selective downregulation of prostaglandin E2-related pathways by the Th2 cytokine IL-13. *J Allergy Clin Immunol*. 2006; 117(6):1446–54. [PubMed: 16751012]
16. Fahy JV, Boushey HA, Lazarus SC, Mauger EA, Cherniack RM, Chinchilli VM, et al. Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. *Am J Respir Crit Care Med*. 2001; 163(6):1470–5. [PubMed: 11371420]
17. van den Toorn LM, Overbeek SE, de Jongste JC, Leman K, Hoogsteden HC, Prins JB. Airway inflammation is present during clinical remission of atopic asthma. *Am J Respir Crit Care Med*. 2001; 164(11):2107–13. [PubMed: 11739143]
18. Hamid Q, Springall DR, Riveros-Moreno V, Chanez P, Howarth P, Redington A, et al. Induction of nitric oxide synthase in asthma. *Lancet*. 1993; 342(8886–8887):1510–3. [PubMed: 7504773]
19. Spallarossa D, Battistini E, Silvestri M, Sabatini F, Biraghi MG, Rossi GA. Time-dependent changes in orally exhaled nitric oxide and pulmonary functions induced by inhaled corticosteroids in childhood asthma. *J Asthma*. 2001; 38(7):545–53. [PubMed: 11714077]
20. Miraglia del Giudice M, Piacentini GL, Capasso M, Capristo C, Maiello N, Boner AL, et al. Formoterol, montelukast, and budesonide in asthmatic children: effect on lung function and exhaled nitric oxide. *Respir Med*. 2007; 101(8):1809–13. [PubMed: 17418554]
21. Silkoff PE, McClean P, Spino M, Erlich L, Slutsky AS, Zamel N. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. *Chest*. 2001; 119(5):1322–8. [PubMed: 11348935]
22. Redington AE, Meng QH, Springall DR, Evans TJ, Creminon C, Maclof J, et al. Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment. *Thorax*. 2001; 56(5):351–7. [PubMed: 11312402]
23. Sugiura H, Komaki Y, Koarai A, Ichinose M. Nitrate stress in refractory asthma. *J Allergy Clin Immunol*. 2008; 121(2):355–60. [PubMed: 18158173]
24. Suresh V, Mih JD, George SC. Measurement of IL-13-induced iNOS-derived gas phase nitric oxide in human bronchial epithelial cells. *Am J Respir Cell Mol Biol*. 2007; 37(1):97–104. [PubMed: 17347445]

25. Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. *J Allergy Clin Immunol.* 2008; 121(3):685–91. [PubMed: 18328894]
26. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. *Lancet.* 2007; 370(9596):1422–31. [PubMed: 17950857]
27. Guo FH, Uetani K, Haque SJ, Williams BR, Dweik RA, Thunnissen FB, et al. Interferon gamma and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. *J Clin Invest.* 1997; 100(4):829–38. [PubMed: 9259582]
28. Kam JC, Szeffler SJ, Surs W, Sher ER, Leung DY. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. *J Immunol.* 1993; 151(7):3460–6. [PubMed: 8376786]
29. Tliba O, Damera G, Banerjee A, Gu S, Baidouri H, Keslacy S, et al. Cytokines induce an early steroid resistance in airway smooth muscle cells: novel role of interferon regulatory factor-1. *Am J Respir Cell Mol Biol.* 2008; 38(4):463–72. [PubMed: 17947510]
30. King NE, Rothenberg ME, Zimmermann N. Arginine in asthma and lung inflammation. *J Nutr.* 2004; 134(10 Suppl):2830S–6S. discussion 53S. [PubMed: 15465795]
31. North ML, Khanna N, Marsden PA, Grasemann H, Scott JA. Functionally important role for arginase 1 in the airway hyperresponsiveness of asthma. *Am J Physiol Lung Cell Mol Physiol.* 2009; 296(6):L911–20. [PubMed: 19286931]
32. Klasen S, Hammermann R, Fuhrmann M, Lindemann D, Beck KF, Pfeilschifter J, et al. Glucocorticoids inhibit lipopolysaccharide-induced up-regulation of arginase in rat alveolar macrophages. *Br J Pharmacol.* 2001; 132(6):1349–57. [PubMed: 11250887]
33. Flynn NE, Meininger CJ, Kelly K, Ing NH, Morris SM Jr, Wu G. Glucocorticoids mediate the enhanced expression of intestinal type II arginase and argininosuccinate lyase in postweaning pigs. *J Nutr.* 1999; 129(4):799–803. [PubMed: 10203553]
34. Ozaki M, Gotoh T, Nagasaki A, Miyanaka K, Takeya M, Fujiyama S, et al. Expression of arginase II and related enzymes in the rat small intestine and kidney. *J Biochem.* 1999; 125(3):586–93. [PubMed: 10050048]
35. Klasen S, Hammermann R, Fuhrmann M, Lindemann D, Beck KF, Pfeilschifter J, et al. Glucocorticoids inhibit lipopolysaccharide-induced up-regulation of arginase in rat alveolar macrophages. *Br J Pharmacol.* 2001; 132 (6):1349–57. [PubMed: 11250887]
36. Gotoh T, Mori M. Arginase II downregulates nitric oxide (NO) production and prevents NO-mediated apoptosis in murine macrophage-derived RAW 264.7 cells. *J Cell Biol.* 1999; 144(3):427–34. [PubMed: 9971738]
37. Morris SM Jr, Kepka-Lenhart D, Chen LC. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. *Am J Physiol.* 1998; 275 (5 Pt 1):E740–7. [PubMed: 9814991]
38. Balint B, Kharitonov SA, Hanazawa T, Donnelly LE, Shah PL, Hodson ME, et al. Increased nitrotyrosine in exhaled breath condensate in cystic fibrosis. *Eur Respir J.* 2001; 17(6):1201–7. [PubMed: 11491165]
39. Xia Y, Zweier JL. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. *Proc Natl Acad Sci U S A.* 1997; 94(13):6954–8. [PubMed: 9192673]
40. Fitzpatrick AM, Teague WG, Holguin F, Yeh M, Brown LA. Severe Asthma Research Program. Airway glutathione homeostasis is altered in children with severe asthma: evidence for oxidant stress. *J Allergy Clin Immunol.* 2009; 123(1):146–152.e8. [PubMed: 19130935]
41. Comhair SA, Xu W, Ghosh S, Thunnissen FB, Almasan A, Calhoun WJ, Janocha AJ, Zheng L, Hazen SL, Erzurum SC. Superoxide dismutase inactivation in pathophysiology of asthmatic airway remodeling and reactivity. *Am J Pathol.* 2005; 166(3):663–74. [PubMed: 15743779]
42. Fitzpatrick AM, Stephenson ST, Hadley GR, Burwell L, Penugonda M, Simon DM, et al. Thiol redox disturbances in children with severe asthma are associated with posttranslational modification of the transcription factor nuclear factor (erythroid-derived 2)–like 2. *J Allergy Clin Immunol.* 2011; 127:1604–11. [PubMed: 21514635]

43. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci U S A*. 1990; 87(4):1620–4. [PubMed: 2154753]
44. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. *Am J Physiol*. 1995; 268(5 Pt 1):L699–722. [PubMed: 7762673]
45. MacPherson JC, Comhair SA, Erzurum SC, Klein DF, Lipscomb MF, Kavuru MS, et al. Eosinophils are a major source of nitric oxide-derived oxidants in severe asthma: characterization of pathways available to eosinophils for generating reactive nitrogen species. *J Immunol*. 2001; 166(9):5763–72. [PubMed: 11313420]

Figure 1a

Figure 1b

Fig. 1.

(a) iNOS mRNA expression and severity iNOS mRNA was higher in severe asthma than in NC, and marginally higher than Mild ($P = 0.02$) and Mild/Mod + ICS ($P = 0.02$). (b) iNOS protein and severity. iNOS protein was significantly higher in Severe than in NCs and marginally higher than in Mild/Mod + ICS ($P = 0.02$).

Fig. 2. Representative western blot of iNOS, arginase 1, arginase 2 protein. Representative blots of iNOS by asthma severity. Stronger expression of arginase 2 as compared to arginase 2 in HAECs.

Figure3a

Figure 3b

Fig. 3.

(a) Controlling iNOS mRNA to arginase 2 mRNA and severity. Indexing iNOS mRNA to arginase 2 significantly improved the differences among the asthmatic groups compared to iNOS mRNA alone. (b) Controlling iNOS protein for arginase 2 and severity. Controlling iNOS protein for arginase 2 expression did not improve the differentiation of severe asthma, but better distinguished Mild asthma from NC.

Figure 4a

Figure 4b

Fig. 4.

(a) FeNO and severity. FeNO was compared between NC, Mild, Mild/Mod + ICS and Severe subjects. FeNO differentiated severe asthma from NC but did not differentiate overall asthma severity, except by trend analysis. (b) 25 KDa nitrotyrosine band and severity. NT levels differed between asthmatics and NC but did not differentiate asthma severity. A representative Nitrotyrosine Western Blot with the prominent 25 KDa band is shown.

Table 1

Demographics

	Normal control	Mild Asthma (no ICS)	Mild-Moderate Asthma+ ICS	Severe Asthma	P-value
Gender (M / F)	14/11	1 / 7	5 / 11	12/ 23	NS
Age (years) *	27(24–45)	39(26–48)	29(23–36)	42(33–51)	p=0.01
FEV1%predicted **	100.6±2.1	91.9±3.2	89.0±4.7	55.3±3.6	P<0.0001
FEV1/ FVC (%) **	80.6±0.9	78.6±2.6	77.3±2.0	57.7±1.9	P<0.0001
ICS	0/25	0/8	16/16	33/35	N/A
Oral GC	0/25	0/8	0/16	26/35	N/A
Atopy	12/25	8/8	14/16	27/35	P=0.005
% Eosinophils in sputum *	0.4(0.0–1.2)	1.0(0.08–7.7)	1.1(0.3–2.0)	4.3(0.8–18.6)	P=0.001

* median with 25th–75th percentiles

** mean±SEM

Table 2

Predictors of FeNO in All subjects and in not severe and severe asthma subjects

	All subjects	n	Not severe	n	Severe	n
iNOS mRNA	r=0.61 p<0.0001	69	r=0.59 p=0.009	18	r=0.49 p=0.006	31
iNOS/Arg2 mRNA	r=0.58 p<0.0001	69	r=0.59 p=0.01	18	r=0.58 p=0.0007	31
iNOS protein	r=0.61 p<0.0001	59	r=0.52 p=0.03	17	r=0.53 p=0.008	24
iNOS/Arg2 protein	r=0.51 p<0.0001	59	r=0.35 p=0.17	17	r=0.46 p=0.02	24

Table 3

Predictors of nitrotyrosine (25kDa) All subjects and in not severe and severe asthma subjects

	All subjects	n	Not severe	n	Severe	n
FeNO	r=0.52 p=0.0009	37	r=0.27 p=0.45	10	r=0.54 p=0.02	17
iNOS mRNA	r=0.53 p=0.002	31	r=0.24 p=0.57	8	r=0.25 p=0.36	15
iNOS/Arg2 mRNA	r=0.34 p=0.06	31	r=0.02 p=0.96	8	r=0.20 p=0.47	15
iNOS protein	r=0.48 p=0.003	37	r=0.15 p=0.68	10	r=0.61 p=0.009	17
iNOS/Arg2 protein	r=0.45 p=0.005	37	r=0.15 p=0.68	10	r=0.63 p=0.006	17

Table 4

Predictors of sputum eosinophils in All subjects and in not severe and severe subjects

	All subjects	n	Not severe	n	Severe	n
FeNO	r=0.43 p=0.0003	65	r=0.31 p=0.17	21	r=0.54 p=0.008	23
iNOS mRNA	r=0.33 p=0.009	63	r=0.24 p=0.32	19	r=0.29 p=0.18	23
iNOS/Arg2 mRNA	r=0.28 p=0.03	63	r=-0.05 p=0.83	19	r=0.26 p=0.22	23
iNOS protein	r=0.30 p=0.03	56	r=0.10 p=0.70	18	r=0.53 p=0.02	20
iNOS/Arg2 protein	r=0.28 p=0.04	56	r=0.19 p=0.44	18	r=0.31 p=0.18	20
25KDa nitrotyrosine	r=0.36 p=0.048	30	r=0.07 p=0.86	9	r=0.64 p=0.02	13